Continuing deterioration in operating performance and intense pricing pressure from competitors were tough pills to swallow for generic pharmaceutical manufacturer Lannett Company, Inc., ultimately leading to its bankruptcy.
Explore our new FAST Rating and Risk Level enhancements in our on-demand webinar.